Retatrutide 10mg
£100.00
Pound sterling (£) - GBP
Retatrutide 10mg
This information is for general knowledge and should not be taken as medical advice. Always consult with a qualified healthcare professional before making any decisions about your health or treatment plan.
Retatrutide is an investigational drug being developed by Eli Lilly for weight loss and obesity management. It is designed to target three hormone receptors: glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG).Â
Potential benefits
- Weight Loss:Â In Phase 2 clinical trials, a 10 mg dose was used as part of a dosage escalation regimen. Studies indicated that doses of Retatrutide were associated with significant weight loss. Research suggests the triple-receptor action of Retatrutide may contribute to more substantial weight loss compared to some other medications.
- Improved Metabolic Health:Â Studies suggest that Retatrutide may improve insulin sensitivity, blood sugar control, and reduce liver fat.
- Reduced Risk of Obesity-Related Diseases:Â The drug could potentially lower the risk of developing conditions like fatty liver disease, heart disease, and Type 2 diabetes.Â
Side effects
- Gastrointestinal Issues:Â The most commonly reported side effects in trials were gastrointestinal, including nausea, vomiting, diarrhea, and constipation.
- Other Side Effects:Â Some individuals reported headaches, fatigue, and dizziness.Â
Availability
Retatrutide is currently an investigational drug and is not approved by the FDA. It is only available to participants in clinical trials or for research purposes. Compounding pharmacies are not permitted to produce or dispense Retatrutide.Â
Important considerations
- Individuals interested in Retatrutide should consult with a healthcare professional to determine if it is a suitable option for them and to discuss potential risks and benefits.
- It’s important to be aware of the possibility of side effects and to follow any instructions provided by a healthcare professional carefully.
- Caution is advised when obtaining Retatrutide through online sources, as the FDA has warned against the use ofÂ
This information is for general knowledge and should not be taken as medical advice. Always consult with a qualified healthcare professional before making any decisions about your health or treatment plan.
Retatrutide is an investigational drug being developed by Eli Lilly for weight loss and obesity management. It is designed to target three hormone receptors: glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG).
We offer complimentary express shipping.
Free returns are available worldwide. If your item is eligible for return, you have 30 days from the date you receive your order to follow this procedure.
See delivery and returns for more information.
Shop The Look
